CG Oncology (CGON) Operating Income (2023 - 2026)
CG Oncology's (CGON) quarterly Operating Income came in at -$66.4 million in Q1 2026, down 57.3% YoY from -$155.5 million in Q1 2025, and down 36.32% on a QoQ basis from -$48.7 million in Q4 2025.
CG Oncology (CGON) Operating Income (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Operating Income data on file, last reported at -$66.4 million in Q1 2026.
- Quarterly Operating Income fell 57.3% year-over-year to -$66.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215.0 million (down 59.94% YoY) and the FY2025 annual result came in at -$190.8 million, down 66.37% from the prior year.
- Operating Income fell to -$66.4 million in Q1 2026, from -$48.7 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$9.7 million in Q1 2023 to a low of -$66.4 million in Q1 2026.
- A 4-year average of -$32.9 million and a median of -$28.3 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income tumbled 131.14% — and 2025, when it dropped 27.99%.
- Tracing CGON's Operating Income over 4 years: stood at -$19.4 million in 2023, then plunged by 96.58% to -$38.0 million in 2024, then dropped by 27.99% to -$48.7 million in 2025, then tumbled by 36.32% to -$66.4 million in 2026.
- The last three Operating Income figures came in at -$66.4 million (Q1 2026), -$48.7 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -86.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -86.40 Mn |
| Mar 31, 2026 | -66.39 Mn |
| Dec 31, 2025 | -48.70 Mn |
| Sep 30, 2025 | -51.13 Mn |
| Jun 30, 2025 | -48.74 Mn |
| Mar 31, 2025 | -42.20 Mn |
| Dec 31, 2024 | -38.05 Mn |
| Sep 30, 2024 | -28.30 Mn |
| Jun 30, 2024 | -25.85 Mn |
| Mar 31, 2024 | -22.47 Mn |
| Dec 31, 2023 | -19.36 Mn |
| Sep 30, 2023 | -14.04 Mn |
| Jun 30, 2023 | -12.33 Mn |
| Mar 31, 2023 | -9.72 Mn |